Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced two longitudinal clinical registries which are collecting real-world clinical utility and clinical validity data on EsoGuard Esophageal DNA testing for the detection of esophageal precancer. The Prospective REView of Esophageal Precancer DetectioN in AT-Risk Patients (PREVENT) Registry collects data on EsoGuard testing in the general at-risk population, while the PREVENT-FF Registry focuses exclusively on at-risk firefighters. The Company released positive clinical utility data from an initial combined analysis of patients from both registries.
The PREVENT Registry prospectively enrolls patients with well-established esophageal precancer risk-factors referred by a physician to Lucid for EsoGuard testing. Lucid clinical personnel perform esophageal cell collection using the EsoCheck® Cell Collection Device and Lucid’s CLIA-certified laboratory then performs the EsoGuard test on the sample. Subsequent management, including referral for upper endoscopy, is dictated exclusively by the referring physician. The PREVENT-FF Registry prospectively enrolls firefighters with additional esophageal precancer risk factors referred for EsoGuard testing who participate in one of Lucid’s #CheckYourFoodTube Precancer Testing Events. A total of 624 patients have been enrolled in the two registries to date.
Also Read: Apple unveils M3, M3 Pro, and M3 Max, the most advanced chips for a personal computer
“PREVENT and PREVENT-FF are key pillars of our commercial strategy for EsoGuard and we are excited to see the initial fruits of our investment in these real-world clinical registries,” said Lishan Aklog, M.D., Lucid’s Chairman & Chief Executive Officer. “The initial combined analysis will supplement our growing clinical utility evidence base, including the previously announced CLUE and San Antonio Firefighter studies. The PREVENT and PREVENT-FF registries, however, are designed to generate a much broader data set than these clinical utility studies. The registries are open-ended, and our goal is to enroll a substantial proportion of all patients undergoing EsoGuard testing by Lucid personnel at Lucid Test Centers, including satellite testing at physician offices, and health fairs, including at fire departments. They also penetrate much further into the patient journey than the previously reported studies by going beyond the initial medical decision-making. The registries have a meaningful longitudinal follow-up period and include confirmatory endoscopy findings in those with positive EsoGuard results. As a result, they will provide both clinical utility and clinical validity data to further support our ongoing commercial and market access efforts, including our critical, expanding engagement with commercial payors. The full data set will also feed our active research and development program on the EsoGuard assay and a pipeline of potential future commercial products. Finally, the PREVENT-FF registry is a testament to our deep commitment to provide access to early precancer detection to reduce the tragic toll that cancer inflicts on firefighters who sacrifice so much for us.”
SOURCE: PRNewswire